Cargando…
Human antibodies against the myelin oligodendrocyte glycoprotein can cause complement-dependent demyelination
BACKGROUND: Antibodies to the myelin oligodendrocyte glycoprotein (MOG) are associated with a subset of inflammatory demyelinating diseases of the central nervous system such as acute disseminated encephalomyelitis and neuromyelitis optica spectrum disorders. However, whether human MOG antibodies ar...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5657084/ https://www.ncbi.nlm.nih.gov/pubmed/29070051 http://dx.doi.org/10.1186/s12974-017-0984-5 |
_version_ | 1783273818246086656 |
---|---|
author | Peschl, Patrick Schanda, Kathrin Zeka, Bleranda Given, Katherine Böhm, Denise Ruprecht, Klemens Saiz, Albert Lutterotti, Andreas Rostásy, Kevin Höftberger, Romana Berger, Thomas Macklin, Wendy Lassmann, Hans Bradl, Monika Bennett, Jeffrey L. Reindl, Markus |
author_facet | Peschl, Patrick Schanda, Kathrin Zeka, Bleranda Given, Katherine Böhm, Denise Ruprecht, Klemens Saiz, Albert Lutterotti, Andreas Rostásy, Kevin Höftberger, Romana Berger, Thomas Macklin, Wendy Lassmann, Hans Bradl, Monika Bennett, Jeffrey L. Reindl, Markus |
author_sort | Peschl, Patrick |
collection | PubMed |
description | BACKGROUND: Antibodies to the myelin oligodendrocyte glycoprotein (MOG) are associated with a subset of inflammatory demyelinating diseases of the central nervous system such as acute disseminated encephalomyelitis and neuromyelitis optica spectrum disorders. However, whether human MOG antibodies are pathogenic or an epiphenomenon is still not completely clear. Although MOG is highly conserved within mammals, previous findings showed that not all human MOG antibodies bind to rodent MOG. We therefore hypothesized that human MOG antibody-mediated pathology in animal models may only be evident using species-specific MOG antibodies. METHODS: We screened 80 human MOG antibody-positive samples for their reactivity to mouse and rat MOG using either a live cell-based assay or immunohistochemistry on murine, rat, and human brain tissue. Selected samples reactive to either human MOG or rodent MOG were subsequently tested for their ability to induce complement-mediated damage in murine organotypic brain slices or enhance demyelination in an experimental autoimmune encephalitis (EAE) model in Lewis rats. The MOG monoclonal antibody 8-18-C5 was used as a positive control. RESULTS: Overall, we found that only a subset of human MOG antibodies are reactive to mouse (48/80, 60%) or rat (14/80, 18%) MOG. Purified serum antibodies from 10 human MOG antibody-positive patients (8/10 reactive to mouse MOG, 6/10 reactive to rat MOG), 3 human MOG-negative patients, and 3 healthy controls were tested on murine organotypic brain slices. Purified IgG from one patient with high titers of anti-human, mouse, and rat MOG antibodies and robust binding to myelin tissue produced significant, complement-mediated myelin loss in organotypic brain slices, but not in the EAE model. Monoclonal 8-18-C5 MOG antibody caused complement-mediated demyelination in both the organotypic brain slice model and in EAE. CONCLUSION: This study shows that a subset of human MOG antibodies can induce complement-dependent pathogenic effects in a murine ex vivo animal model. Moreover, a high titer of species-specific MOG antibodies may be critical for demyelinating effects in mouse and rat animal models. Therefore, both the reactivity and titer of human MOG antibodies must be considered for future pathogenicity studies. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12974-017-0984-5) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5657084 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-56570842017-10-31 Human antibodies against the myelin oligodendrocyte glycoprotein can cause complement-dependent demyelination Peschl, Patrick Schanda, Kathrin Zeka, Bleranda Given, Katherine Böhm, Denise Ruprecht, Klemens Saiz, Albert Lutterotti, Andreas Rostásy, Kevin Höftberger, Romana Berger, Thomas Macklin, Wendy Lassmann, Hans Bradl, Monika Bennett, Jeffrey L. Reindl, Markus J Neuroinflammation Research BACKGROUND: Antibodies to the myelin oligodendrocyte glycoprotein (MOG) are associated with a subset of inflammatory demyelinating diseases of the central nervous system such as acute disseminated encephalomyelitis and neuromyelitis optica spectrum disorders. However, whether human MOG antibodies are pathogenic or an epiphenomenon is still not completely clear. Although MOG is highly conserved within mammals, previous findings showed that not all human MOG antibodies bind to rodent MOG. We therefore hypothesized that human MOG antibody-mediated pathology in animal models may only be evident using species-specific MOG antibodies. METHODS: We screened 80 human MOG antibody-positive samples for their reactivity to mouse and rat MOG using either a live cell-based assay or immunohistochemistry on murine, rat, and human brain tissue. Selected samples reactive to either human MOG or rodent MOG were subsequently tested for their ability to induce complement-mediated damage in murine organotypic brain slices or enhance demyelination in an experimental autoimmune encephalitis (EAE) model in Lewis rats. The MOG monoclonal antibody 8-18-C5 was used as a positive control. RESULTS: Overall, we found that only a subset of human MOG antibodies are reactive to mouse (48/80, 60%) or rat (14/80, 18%) MOG. Purified serum antibodies from 10 human MOG antibody-positive patients (8/10 reactive to mouse MOG, 6/10 reactive to rat MOG), 3 human MOG-negative patients, and 3 healthy controls were tested on murine organotypic brain slices. Purified IgG from one patient with high titers of anti-human, mouse, and rat MOG antibodies and robust binding to myelin tissue produced significant, complement-mediated myelin loss in organotypic brain slices, but not in the EAE model. Monoclonal 8-18-C5 MOG antibody caused complement-mediated demyelination in both the organotypic brain slice model and in EAE. CONCLUSION: This study shows that a subset of human MOG antibodies can induce complement-dependent pathogenic effects in a murine ex vivo animal model. Moreover, a high titer of species-specific MOG antibodies may be critical for demyelinating effects in mouse and rat animal models. Therefore, both the reactivity and titer of human MOG antibodies must be considered for future pathogenicity studies. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12974-017-0984-5) contains supplementary material, which is available to authorized users. BioMed Central 2017-10-25 /pmc/articles/PMC5657084/ /pubmed/29070051 http://dx.doi.org/10.1186/s12974-017-0984-5 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Peschl, Patrick Schanda, Kathrin Zeka, Bleranda Given, Katherine Böhm, Denise Ruprecht, Klemens Saiz, Albert Lutterotti, Andreas Rostásy, Kevin Höftberger, Romana Berger, Thomas Macklin, Wendy Lassmann, Hans Bradl, Monika Bennett, Jeffrey L. Reindl, Markus Human antibodies against the myelin oligodendrocyte glycoprotein can cause complement-dependent demyelination |
title | Human antibodies against the myelin oligodendrocyte glycoprotein can cause complement-dependent demyelination |
title_full | Human antibodies against the myelin oligodendrocyte glycoprotein can cause complement-dependent demyelination |
title_fullStr | Human antibodies against the myelin oligodendrocyte glycoprotein can cause complement-dependent demyelination |
title_full_unstemmed | Human antibodies against the myelin oligodendrocyte glycoprotein can cause complement-dependent demyelination |
title_short | Human antibodies against the myelin oligodendrocyte glycoprotein can cause complement-dependent demyelination |
title_sort | human antibodies against the myelin oligodendrocyte glycoprotein can cause complement-dependent demyelination |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5657084/ https://www.ncbi.nlm.nih.gov/pubmed/29070051 http://dx.doi.org/10.1186/s12974-017-0984-5 |
work_keys_str_mv | AT peschlpatrick humanantibodiesagainstthemyelinoligodendrocyteglycoproteincancausecomplementdependentdemyelination AT schandakathrin humanantibodiesagainstthemyelinoligodendrocyteglycoproteincancausecomplementdependentdemyelination AT zekableranda humanantibodiesagainstthemyelinoligodendrocyteglycoproteincancausecomplementdependentdemyelination AT givenkatherine humanantibodiesagainstthemyelinoligodendrocyteglycoproteincancausecomplementdependentdemyelination AT bohmdenise humanantibodiesagainstthemyelinoligodendrocyteglycoproteincancausecomplementdependentdemyelination AT ruprechtklemens humanantibodiesagainstthemyelinoligodendrocyteglycoproteincancausecomplementdependentdemyelination AT saizalbert humanantibodiesagainstthemyelinoligodendrocyteglycoproteincancausecomplementdependentdemyelination AT lutterottiandreas humanantibodiesagainstthemyelinoligodendrocyteglycoproteincancausecomplementdependentdemyelination AT rostasykevin humanantibodiesagainstthemyelinoligodendrocyteglycoproteincancausecomplementdependentdemyelination AT hoftbergerromana humanantibodiesagainstthemyelinoligodendrocyteglycoproteincancausecomplementdependentdemyelination AT bergerthomas humanantibodiesagainstthemyelinoligodendrocyteglycoproteincancausecomplementdependentdemyelination AT macklinwendy humanantibodiesagainstthemyelinoligodendrocyteglycoproteincancausecomplementdependentdemyelination AT lassmannhans humanantibodiesagainstthemyelinoligodendrocyteglycoproteincancausecomplementdependentdemyelination AT bradlmonika humanantibodiesagainstthemyelinoligodendrocyteglycoproteincancausecomplementdependentdemyelination AT bennettjeffreyl humanantibodiesagainstthemyelinoligodendrocyteglycoproteincancausecomplementdependentdemyelination AT reindlmarkus humanantibodiesagainstthemyelinoligodendrocyteglycoproteincancausecomplementdependentdemyelination |